Home Cart Sign in  
Chemical Structure| 934493-76-2 Chemical Structure| 934493-76-2

Structure of Voxtalisib
CAS No.: 934493-76-2

Chemical Structure| 934493-76-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Voxtalisib is a potent and highly selective inhibitor of class I PI3Ks with IC50 of 39/110/9/43 nM for PI3Kα/β/γ/δ, also inhibits mTOR with IC50 of 160-910 nM.

Synonyms: XL765; SAR245409

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Voxtalisib

CAS No. :934493-76-2
Formula : C13H14N6O
M.W : 270.29
SMILES Code : CCN1C2=NC(N)=NC(C)=C2C=C(C3=NNC=C3)C1=O
Synonyms :
XL765; SAR245409
MDL No. :MFCD20276656
InChI Key :RGHYDLZMTYDBDT-UHFFFAOYSA-N
Pubchem ID :16123056

Safety of Voxtalisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Voxtalisib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110γ

    PI3Kγ, IC50:9 nM

  • p110β

    PI3Kβ, IC50:113 nM

  • p110α

    PI3Kα, IC50:39 nM

  • p110δ

    PI3Kδ, IC50:43 nM

  • mTOR

    mTOR, IC50:157 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
U87IDHmut cells 12 μM 24 hours To evaluate the effect of XL765 on U87IDHmut cell proliferation, showing a 61.0 ± 10.6% reduction in cell number. PMC6642106
MDA-MB-231 IC50 75.2 µM 24 hours Investigate the effect of XL765 on circRNA and linRNA expression, showing upregulation of circRNA and downregulation of linRNA PMC10204552
MCF-7 IC50 91.4 µM 24 hours Investigate the effect of XL765 on circRNA and linRNA expression, showing upregulation of circRNA and downregulation of linRNA PMC10204552
Chronic lymphocytic leukemia cells 0.86 µM (IC50) 48 hours Therapeutic effect on chronic lymphocytic leukemia through apoptotic caspase-dependent mechanisms and effectively inhibits T-cell-mediated cytokine production PMC9237521
SUM149 and MDA-MB-231 0.5 µM 6 hours To assess the effect of combination treatment on TNBC cell migration and invasion capabilities PMC4643087
NHAIDHmut cells 32 μM 72 hours To evaluate the effect of XL765 on NHAIDHmut cell proliferation, showing a 55.7 ± 16% reduction in cell number. PMC6642106
GBM 39 5.0 μM 72 hours Evaluate the cytotoxicity of XL765 on GBM 39 cells, showing a concentration-dependent decrease in cell viability PMC3064692
GBM GS-2 7.7 μM 72 hours Evaluate the cytotoxicity of XL765 on GBM GS-2 cells, showing a concentration-dependent decrease in cell viability PMC3064692
GBM 12 3.7 μM 72 hours Evaluate the cytotoxicity of XL765 on GBM 12 cells, showing a concentration-dependent decrease in cell viability PMC3064692
GBM 8 5.7 μM 72 hours Evaluate the cytotoxicity of XL765 on GBM 8 cells, showing a concentration-dependent decrease in cell viability PMC3064692
SUM149 TNBC cells 0.005-20 μM 72 hours Evaluate the synergistic effect of Voxtalisib with birinapant, results showed no significant synergistic effect observed in SUM149 cells PMC8747014
MDA-MB-231 40 nM 72 hours To evaluate the synergistic inhibitory effect of PI3K inhibitor SAR245409 combined with MEK inhibitor AS703026 on TNBC cell proliferation PMC4643087
ST88 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with an IC50 of 2.49 μM PMC3416967
MPNST642 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with an IC50 of 1.93 μM PMC3416967
STS26T 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with an IC50 of 1.75 μM PMC3416967
MPNST724 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with an IC50 of 0.86 μM PMC3416967
S462 0.25-20 μM 96 hours XL765 significantly inhibited MPNST cell growth with an IC50 of 0.81 μM PMC3416967

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice U87IDHmut intracranial tumor model Oral 30 mg/kg Twice daily, continuous treatment To evaluate the effect of XL765 on U87IDHmut intracranial tumor model, showing that XL765 treatment significantly prolonged animal survival. PMC6642106
Mice Gastrointestinal stromal tumor (GIST) model Oral gavage 30 mg/kg (6-hour treatment), 20 mg/kg (7-day treatment) Single dose for 6-hour treatment or twice daily for 7-day treatment To evaluate the effect of Voxtalisib on GIST tumor proliferation. Results showed that 6-hour treatment inhibited PI3K signaling (pAKT, pS6, and p4EBP1) but increased MAPK phosphorylation. Seven days of treatment reduced tumor cell proliferation by 70%. PMC5635919
SCID mice MPNST724 and STS26T xenograft models Oral 30 mg/kg/bid Twice daily, continuous treatment XL765 significantly inhibited local and metastatic growth of MPNST xenografts PMC3416967
Nude mice GS-2 and U87-MG GBM orthotopic models Oral 30mg/kg voxtalisib twice daily Twice daily, continuous treatment To monitor the effect of voxtalisib alone or in combination with TMZ, finding a significantly lower lactate-to-pyruvate ratio post-treatment, associated with enhanced survival PMC4873419
Mice Aldh5a1−/− mouse model Intraperitoneal injection 5 mg/kg/day and 10 mg/kg/day Once daily until death To evaluate the effects of mTOR inhibitors on lifespan and body weight in aldh5a1?/? mice. Results showed that Tor2, XL-765, and tat-Bec1 significantly extended lifespan and improved body weight. PMC5114712
Nude mice Intracranial xenograft GBM 39 model Oral gavage 50 mg/kg Twice daily, 6 hours apart, for 2 weeks Evaluate the inhibitory effect of XL765 on GBM 39 tumor growth in vivo, showing a 13-fold reduction in median tumor bioluminescence and improvement in median survival compared to control PMC3064692

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01410513 Indolent Non-Hodgkin Lymphoma|... More >>Mantle Cell Lymphoma|Chronic Lymphocytic Leukemia Less << PHASE1 COMPLETED 2025-05-14 Investigational Site Number 84... More >>0004, Aurora, Colorado, 80045, United States|Investigational Site Number 840006, Augusta, Georgia, 30912, United States|Investigational Site Number 840002, Charleston, South Carolina, 29406, United States Less <<
NCT01403636 Lymphoma PHASE2 COMPLETED 2025-09-14 Investigational Site Number 84... More >>0012, Los Angeles, California, 90033, United States|Investigational Site Number 840104, Fort Meyers, Florida, 33919, United States|Investigational Site Number 840006, Augusta, Georgia, 30912, United States|Investigational Site Number 840011, Maywood, Illinois, 60153, United States|Investigational Site Number 840010, Kansas City, Kansas, 66160-7321, United States|Investigational Site Number 840013, Lexington, Kentucky, 40536, United States|Investigational Site Number 840007, Paducah, Kentucky, 42002, United States|Investigational Site Number 840004, Boston, Massachusetts, 02115, United States|Investigational Site Number 840015, St Louis, Missouri, 63110, United States|Investigational Site Number 840014, Canton, Ohio, 44718, United States|Investigational Site Number 840001, Philadelphia, Pennsylvania, 19111, United States|Investigational Site Number 840002, Morgantown, West Virginia, 26506, United States|Investigational Site Number 036002, Clayton, 3168, Australia|Investigational Site Number 036001, Hobart, 7001, Australia|Investigational Site Number 036005, Kingswood, 2747, Australia|Investigational Site Number 036003, Perth, 6000, Australia|Investigational Site Number 056003, Bruxelles, 1000, Belgium|Investigational Site Number 056002, Gent, 9000, Belgium|Investigational Site Number 056001, Leuven, 3000, Belgium|Investigational Site Number 250002, Montpellier, 34295, France|Investigational Site Number 250001, Pierre Benite Cedex, 69495, France|Investigational Site Number 250004, Rennes, 35033, France|Investigational Site Number 250005, Rouen Cedex, 76038, France|Investigational Site Number 250003, Villejuif Cedex, 94805, France|Investigational Site Number 276003, Frankfurt Am Main, 60590, Germany|Investigational Site Number 276002, Jena, 07747, Germany|Investigational Site Number 276001, Ulm, 89081, Germany|Investigational Site Number 528001, Amsterdam, 1105 AZ, Netherlands|Investigational Site Number 528003, Groningen, 9713 GZ, Netherlands|Investigational Site Number 528002, Rotterdam, 3075 EA, Netherlands Less <<
NCT01596270 Neoplasm Malignant PHASE1 COMPLETED 2025-10-14 Investigational Site Number 84... More >>0001, Detroit, Michigan, 48201, United States|Investigational Site Number 840002, New Brunswick, New Jersey, 08903, United States|Investigational Site Number 840003, Dallas, Texas, 75230, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.50mL

3.70mL

1.85mL

37.00mL

7.40mL

3.70mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories